Reports Q4 revenue $4.99M vs. $353,000 last year. “LAVA’s approach to maximize shareholder value in 2025 will focus on evaluating strategic options while continuing to enroll patients in our ongoing Phase 1 study of LAVA-1266, and supporting our pharma partnerships,” said Steve Hurly, Chief Executive Officer of LAVA. “The Phase 1 study of LAVA-1266 as a potential treatment for acute myeloid leukemia and myelodysplastic syndrome is progressing. Looking ahead, with a strong cash balance, we believe LAVA is well-positioned to unlock strategic opportunities, and we look forward to updating investors with our progress throughout the year.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX:
- LVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce Reduction
- Lava Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Lava Therapeutics implements restructuring plan, workforce reduction of 30%
- LAVA Therapeutics Announces Restructuring Plan for 2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue